399 related articles for article (PubMed ID: 15541051)
1. Testosterone therapy in the ageing male: what about the prostate?
Schultheiss D; Machtens S; Jonas U
Andrologia; 2004 Dec; 36(6):355-65. PubMed ID: 15541051
[TBL] [Abstract][Full Text] [Related]
2. The effect of androgen supplementation therapy on the prostate.
Kaufman JM
Aging Male; 2003 Sep; 6(3):166-74. PubMed ID: 14628497
[TBL] [Abstract][Full Text] [Related]
3. [Testosterone substitution in patients with hypogonadism].
Martínez Portillo FJ; Cueva Martínez A; Martin Braun P; Fernández Arancibia MI; Jünemann KP; Alken P
Arch Esp Urol; 2002 Sep; 55(7):827-38. PubMed ID: 12380312
[TBL] [Abstract][Full Text] [Related]
4. Testosterone replacement therapy for late onset hypogonadism: what is the risk of inducing prostate cancer?
Gould DC; Kirby RS
Prostate Cancer Prostatic Dis; 2006; 9(1):14-8. PubMed ID: 16264770
[TBL] [Abstract][Full Text] [Related]
5. Monitoring androgen replacement therapy: testosterone and prostate safety.
Morales A
J Endocrinol Invest; 2005; 28(3 Suppl):122-7. PubMed ID: 16042371
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
Coward RM; Simhan J; Carson CC
BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
[TBL] [Abstract][Full Text] [Related]
7. Prevention of prostate cancer by androgens: experimental paradox or clinical reality.
Algarté-Génin M; Cussenot O; Costa P
Eur Urol; 2004 Sep; 46(3):285-94; discussion 294-5. PubMed ID: 15306098
[TBL] [Abstract][Full Text] [Related]
8. Effect of testosterone administration to men with prostate cancer is unpredictable: a word of caution and suggestions for a registry.
Morales A
BJU Int; 2011 May; 107(9):1369-73. PubMed ID: 21518230
[TBL] [Abstract][Full Text] [Related]
9. Point: urologists should take an active role in the diagnosis and treatment of hypogonadism in the aging male.
Heaton JP
Can J Urol; 2002 Dec; 9(6):1677-80. PubMed ID: 12517308
[TBL] [Abstract][Full Text] [Related]
10. The current status of therapy for symptomatic late-onset hypogonadism with transdermal testosterone gel.
Ebert T; Jockenhövel F; Morales A; Shabsigh R
Eur Urol; 2005 Feb; 47(2):137-46. PubMed ID: 15661407
[TBL] [Abstract][Full Text] [Related]
11. [Safety of long-term replacement hormonal therapy in patients with erectile dysfunction and androgen deficiency].
Morgunov LIu; Vertkin AL; Pushkar' DIu
Urologiia; 2007; (5):49-51. PubMed ID: 18254226
[TBL] [Abstract][Full Text] [Related]
12. Testosterone and ageing: what have we learned since the Institute of Medicine report and what lies ahead?
Miner MM; Seftel AD
Int J Clin Pract; 2007 Apr; 61(4):622-32. PubMed ID: 17343664
[TBL] [Abstract][Full Text] [Related]
13. ISA, ISSAM and EAU recommendations for the investigation, treatment and monitoring of late-onset hypogonadism in males: scientific background and rationale.
Lunenfeld B; Saad F; Hoesl CE
Aging Male; 2005 Jun; 8(2):59-74. PubMed ID: 16096160
[TBL] [Abstract][Full Text] [Related]
14. Testosterone and prostate cancer: revisiting old paradigms.
Isbarn H; Pinthus JH; Marks LS; Montorsi F; Morales A; Morgentaler A; Schulman C
Eur Urol; 2009 Jul; 56(1):48-56. PubMed ID: 19375844
[TBL] [Abstract][Full Text] [Related]
15. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men.
Kaufman JM; Graydon RJ
J Urol; 2004 Sep; 172(3):920-2. PubMed ID: 15310998
[TBL] [Abstract][Full Text] [Related]
16. 5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction.
Rittmaster RS
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):389-402. PubMed ID: 18471794
[TBL] [Abstract][Full Text] [Related]
17. The role of combination medical therapy in benign prostatic hyperplasia.
Greco KA; McVary KT
Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
[TBL] [Abstract][Full Text] [Related]
18. A rational approach to androgen therapy for hypogonadal men with prostate cancer.
Kaufman J
Int J Impot Res; 2006; 18(1):26-31. PubMed ID: 16208401
[TBL] [Abstract][Full Text] [Related]
19. Testosterone and prostate cancer: what are the risks for middle-aged men?
Morgentaler A
Urol Clin North Am; 2011 May; 38(2):119-24. PubMed ID: 21621078
[TBL] [Abstract][Full Text] [Related]
20. Prostate cancer after exogenous testosterone replacement therapy in a patient with pituitary insufficiency.
Halland A; Jønler M; Pedersen KV
Scand J Urol Nephrol; 2005; 39(1):87-8. PubMed ID: 15764279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]